Compare Kimberly Clark Corp (KMB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Viatris Inc — how do they compare? Kimberly Clark Corp trades at $109.39 (market cap $36.11B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| KMB | VTRS | |
|---|---|---|
Market Cap | $36.11B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $134.81 | $17.86 |
52-Week Low | $93.05 | $9.49 |
Enterprise Value | $41.67B | $30.80B |
Dividend Yield | 4.72% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $109.47, up 1.34% today, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings missed estimates due to China diaper disruptions and a distribution center fire, though gross margin expanded. The company maintains a strong dividend yield of 4.7% and an A credit rating. Analyst consensus is a $113.20 price target with 29% buy ratings, but near-term headwinds include softer consumer demand and inventory adjustments.
Outlook remains cautious with 2026 guidance trimmed; the stock offers value at a forward P/E of 14.6x and robust cash flow, but risks from China market volatility and input cost pressures persist. Institutional interest is mixed, with recent filings showing both new positions and trims. Long-term prospects hinge on innovation and productivity gains offsetting cyclical challenges.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
